^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3)

    i
    Other names: NTRK3, TRKC, Neurotrophic tyrosine kinase, receptor, type 3
    1m
    PLAG1-Driven Lipoblastomatosis: Diagnostic Insights from a Case Report and Literature Review. (PubMed, Turk Patoloji Derg)
    Identification of PLAG1 rearrangement is crucial for confirming the diagnosis. With the growing number of molecularly defined soft-tissue tumours of diagnostic and prognostic significance, incorporating molecular analysis is essential in the evaluation of soft-tissue lesions.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • EWSR1 (EWS RNA Binding Protein 1) • CD34 (CD34 molecule) • DDIT3 (DNA-damage-inducible transcript 3) • PLAG1 (PLAG1 Zinc Finger)
    |
    EGFR exon 20 insertion • EGFR exon 20 mutation
    1m
    Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancer. (PubMed, Lung Cancer)
    Pan-TRK IHC has a false-positive rate of ∼4%, particularly in squamous cell carcinomas, underscoring the need for confirmatory NGS to validate IHC findings and assess fusion functionality. Functional NTRK1/2/3 fusions remain exceedingly rare in NSCLC, with a detection rate of 0.03% across our combined cohorts.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    |
    VENTANA pan-TRK (EPR17341) Assay
    2ms
    Clinical, morphological, and genomic features of FGFR fusion Spitz neoplasms. (PubMed, Pathology)
    None of the cases had genomic variants in TERT or CDKN2A. We believe FGFR1 fusions constitute a distinct subtype of Spitz neoplasm and FGFR1 should be added to the list of Spitz-associated genomic fusions.
    Journal
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR1 (Fibroblast growth factor receptor 1) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • FGFR (Fibroblast Growth Factor Receptor) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8)
    |
    FGFR fusion • HRAS mutation
    2ms
    A pilot single-case longitudinal multi-omics of canine oral melanoma characterizes endogenous mutation patterns and radiotherapy-associated responses. (PubMed, Gene)
    Shared differentially expressed genes between tumor and blood post-RT samples suggest that peripheral blood may partially capture systemic molecular responses after RT. These findings offer preliminary insights into the molecular landscape of canine oral melanoma and provide a hypothesis-generating basis for future validation of candidate molecular markers associated with RT response.
    Journal • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • BCL2 (B-cell CLL/lymphoma 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ADAM17 (ADAM Metallopeptidase Domain 17)
    |
    EGFR mutation
    2ms
    Validation of NTRK Fusion Detection Using an Ultrarapid, Fully Automated Cartridge-based PCR Assay. (PubMed, J Mol Diagn)
    Most "Invalid" results were attributable to RNA degradation and resolved with freshly cut sections. These findings support the Idylla GeneFusion Assay as a rapid and practical frontline tool for NTRK fusion detection, particularly in settings with limited tissue or need for expedited decision-making, with reflex next-generation sequencing recommended for "Equivocal" cases or when fusion partner identification is required.
    Journal
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK fusion
    |
    Idylla™ GeneFusion Assay
    2ms
    Case Report: A rare pediatric case of secretory carcinoma of the parotid gland with high-grade components misdiagnosed as pleomorphic adenoma. (PubMed, Front Oncol)
    Intraoperative frozen section examination indicated a pathological diagnosis of low-grade malignant salivary gland tumor. Thus, comprehensive histopathological and molecular analyses are essential, as the morphological features of this tumor may be deceptively bland.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6) • SOX10 (SRY-Box 10) • KRT19 (Keratin 19)
    2ms
    NTRK-rearranged uterine sarcomas with heterologous rhabdomyoblastic and cartilaginous differentiation: expanding the morphological spectrum with discussion of passenger NTRK molecular events. (PubMed, Virchows Arch)
    Our findings expand the morphological and immunohistochemical spectrum of NTRK-rearranged uterine sarcomas, highlight important diagnostic pitfalls and raise the important question of driver versus passenger molecular events. Recognition of tumours with these unusual features is crucial, as NTRK-rearranged sarcomas frequently show aggressive clinical behaviour but are potentially amenable to targeted therapy with selective TRK inhibitors.
    Journal
    |
    TP53 (Tumor protein P53) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • DICER1 (Dicer 1 Ribonuclease III) • NTRK (Neurotrophic receptor tyrosine kinase) • AKAP13 (A-Kinase Anchoring Protein 13) • LZTR1 (Leucine Zipper Like Transcription Regulator 1)
    2ms
    Malignant Progression of Meningiomas: Occurrence, Outcomes, and Underpinning Factors. (PubMed, World Neurosurg)
    Malignant progression in meningiomas appears to reflect a process of clonal evolution shaped by genomic instability and therapeutic selection pressures. In this context, the observed association between irradiation and adverse outcomes underscores the need to critically reassess its role, while surgical resection remains the cornerstone of management.
    Journal
    |
    TP53 (Tumor protein P53) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • ARID1A (AT-rich interaction domain 1A) • NOTCH1 (Notch 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • NOTCH2 (Notch 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • NOTCH3 (Notch Receptor 3) • FANCG (FA Complementation Group G)
    2ms
    Secretory carcinoma of the breast: a report of six cases with different immunophenotypes and molecular subtypes. (PubMed, Histopathology)
    These findings support the existence of greater variability in surrogate and intrinsic molecular subtypes within secretory carcinomas, providing potential personalized therapeutic strategies for the treatment of these patients.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ETV6 (ETS Variant Transcription Factor 6)
    |
    HER-2 expression
    2ms
    TFG-Containing Fusions in Melanocytic Tumors: From Polymorphic Read-Through Transcripts to Oncogenic Kinase Fusions. (PubMed, J Cutan Pathol)
    Recognition of such fusions is essential to avoid misinterpretation, particularly as fusion detection increasingly informs diagnosis and clinical decision-making. These findings underscore the necessity of integrating molecular results with established clinicopathologic frameworks.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • ADGRG7 (Adhesion G Protein-Coupled Receptor G7)
    2ms
    A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations (clinicaltrials.gov)
    P1/2, N=67, Recruiting, D3 Bio (Wuxi) Co., Ltd | Active, not recruiting --> Recruiting | Trial completion date: Apr 2028 --> Aug 2028 | Trial primary completion date: Apr 2028 --> Aug 2028
    Enrollment open • Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    BRAF V600E • EGFR mutation • KRAS G12C • BRAF V600 • EGFR L858R • EGFR T790M • KRAS G12D • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • RET rearrangement • KRAS G12 • KRAS G12S • KRAS Q61
    |
    D3S-002 • elisrasib (D3S-001)